JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus |
| |
| Authors: | Anna Sophie Klaeschen Dominik Wolf Peter Brossart Thomas Bieber Joerg Wenzel |
| |
| Affiliation: | 1. Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany;2. Medical Clinic III, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany |
| |
| Abstract: | ![]()
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE‐typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases. |
| |
| Keywords: | chilblain lupus erythematosus CXCL10 interferon JAK/STAT pathway kinase inhibitor |
|
|
